Cyxone AB is a clinical stage biotech company specializing in the development of transformative therapies against autoimmune and autoinflammatory diseases. Our pipeline includes rabeximod, currently in Phase 2 clinical development for the treatment of rheumatoid arthritis and T20K, currently in early clinical development for the treatment of multiple sclerosis.
Cyxone’s business model is to out-license projects after the Phase 2 clinical trials are done.
Cyxone’s financial statements are prepared in accordance with International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) as adopted by the EU.
Investor Relations contact
Carl-Magnus Högerkorp, CEO